What contraindications should you pay attention to when using filgotinib?

As a highly targeted JAK1 inhibitor, filgotinib has the advantage of treating rheumatoid arthritis in that it can effectively reduce joint inflammation, improve quality of life and delay disease progression. However, due to their immunosuppressive properties, these drugs must strictly follow the indications during clinical use and pay attention to the contraindications of specific groups of people to ensure the safety of patients.

First of all, filgotinib is not recommended for patients with known active infections, especially those with tuberculosis, uncontrolled hepatitis B or C, or severe bacterial or fungal infections. Because the drug regulates immune response by inhibiting the JAK pathway, it may weaken the body's ability to resist infection and increase the risk of infection worsening. Therefore, before starting treatment, a comprehensive infection screening needs to be carried out to ensure that the patient has no active infection. If necessary, medication should be delayed and the underlying infection problem should be dealt with first.

Secondly, filgotinib should also be used with caution in patients with a history of cancer, lymphatic system abnormalities, or severe cardiovascular disease. SomeJAK inhibitors may have potential tumor promotion risks during long-term use. Although filgotinib has a more precise target, in the absence of insufficient accumulation of real-world safety data, careful decisions should be made based on individualized risk assessment. Pregnant and lactating women are among the contraindication groups for this drug. There is insufficient research data to prove its safety during pregnancy, so effective contraceptive measures should be taken during treatment.

Of particular note is the potential risk of filgotinib affecting reproductive function in male patients. Although relevant research is still ongoing, some data show that the drug may affect sperm production. Therefore, men planning to have children should consult a professional doctor during the medication to evaluate the relationship between fertility planning and drug use.

In addition, liver function, blood routine, lipid levels and other indicators should be regularly monitored while taking filgotinib to prevent systemic side effects caused by the drug.

Reference materials:https://go.drugbank.com/drugs/DB14845